Bronx Prevention Center

ICAP’s two research centers in New York, the Bronx Prevention Center and the Harlem Prevention Center, are hubs of research in New York City that have been historically underserved and disproportionately impacted by the HIV epidemic and, more recently, the COVID-19 epidemic. ICAP works with local community-based organizations, religious leaders, and advocates to promote community awareness of, and engagement with the research studies.

The Community Advisory Board (CAB) for the ICAP Clinical Trials Unit (CTU) provides guidance and feedback on proposed studies, outreach strategies, feedback on study materials, and information regarding community perceptions of the potential or current research studies.

Current studies include investigations of antibody-mediated prevention using broadly neutralizing antibodies (bnAbs) to prevent HIV or COVID-19, an injectable long-acting pre-exposure prophylaxis (PrEP) option, mobile technologies to improve PrEP adherence, integrated care for people who inject opiates, HIV vaccine studies, and studies of COVID-19 immunity, vaccine efficacy, and treatment among others.


HPTN 094: The INTEGRA Study

  • current
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care Web Links: https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190 ...

HTPN 083: Give PrEP a Shot

  • current
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.Closed to enrollment, in active study follow-up Web Links: https://clinicaltrials.gov/ct2/show/NCT02720094  https://www.hptn.org/research/studies/hptn083  ...

IMPOWER-022: The Merck Study

  • current
A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as pre-exposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1 infection. Closed to enrollment. In active study follow-up. Web Links: https://clinicaltrials.gov/ct2/show/NCT04644029 ...

Making PrEP Smart

  • current
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking ...

ICAP in Bronx

Program Start


Key Technical Areas
  • Clinical Research and Trials
  • COVID-19 Research
  • PreP Research
Current Funders
  • National Institute of Health
    • National Institute of Allergy and Infectious Diseases (NIH/NIAID)
      Department of Health and Human Services (DHHS)
    • Family Health International (FHI)
    • Fred Hutchinson Cancer Research Center
  • AstraZeneca
  • Merck



Site Leader

Ellen Morrison, MD, MPH

Dr. Ellen Morrison is the site lead and an investigator at the Bronx Prevention Center, a clinical research site that is one of the three sites that comprise the NIH-funded ICAP at Columbia Clinical Trials Unit.  Dr. Morrison leads studies that focus on HIV prevention, including the use of pre-exposure prophylaxis and the provision of integrated services on a mobile van to engage out-of-care injection opiate users in HIV prevention and care.  In addition, a rapid pivot to address the SARS-CoV-2 pandemic has included new projects on COVID-19 vaccines, testing of monoclonal antibodies, and other COVID-19 treatment modalities.  


Jobs in the United States

See the ICAP careers page to search all job listings.